DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call - WMBB News 13 - The Panhandle's News Leader

DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call

  • What's Going Around

  • Wednesday, May 15 2013 11:45 AM EDT2013-05-15 15:45:20 GMT
    While cold and flu season is widely discussed, pneumonia season is quickly gaining the spotlight. One in 20 dies from the lung disease each year, and it's what's going around this week. What is pneumonia? Pneumonia
    While cold and flu season is widely discussed, pneumonia season is quickly gaining the spotlight. One in 20 dies from the lung disease each year, and it's what's going around this week.

  • Wednesday, May 8 2013 9:06 AM EDT2013-05-08 13:06:30 GMT
    We all have our aches in our bellies and backs from time to time, but these pains can also be signs of gallstones. Dr. Hatem Mourad from Coastal Urgent Care and Family Medicine warns that gallstones are
    Dr. Hatem Mourad from Coastal Urgent Care and Family Medicine warns that gallstones are what's going around.

  • Medical Central is the source for local doctors to advertise their businesses, as well as provide clients and viewers with valuable information on their fields of study.
    •   

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE DURECT Corporation

CUPERTINO, Calif., Feb. 22, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 28, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER®, ORADUR®, TRANSDUR®, and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

 

 

 

©2012 PR Newswire. All Rights Reserved.